Levofolino Rūgštis Medac

Levoleucovorin disodium, the active ingredient in Levofolino Rūgštis Medac, is a folate analog (leucovorin) presented as an injectable solution for intravenous use. It is employed to rescue patients from methotrexate toxicity and to supplement folate in deficiency states. The product is manufactured under EU GMP standards and is intended for clinical settings that require rapid folate repletion.

GNH USA supplies Levofolino Rūgštis Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide, ensuring regulatory‑aligned sourcing and reliable logistics.

Levoleucovorin disodium is used in clinical situations that involve folate pathway disruption or high‑dose methotrexate exposure.

Methotrexate toxicity rescue: restores folate‑dependent DNA synthesis and reduces toxic effects in patients receiving methotrexate. Folate deficiency: replenishes reduced folate stores in individuals with documented folate deficiency. High‑dose methotrexate therapy: provides rescue after chemotherapy to protect normal cells while allowing antineoplastic activity.

Levoleucovorin disodium may be associated with a range of adverse reactions, which are classified by frequency.

Common Side Effects: - Nausea - Vomiting - Mild rash or erythema - Transient fever - Headache - Mild elevation of liver enzymes

Serious or Rare Side Effects: - Anaphylactic or severe hypersensitivity reaction - Acute renal failure - Severe electrolyte disturbances (e.g., hyperkalemia, hypomagnesemia) - Pulmonary toxicity (interstitial pneumonitis) - Severe hepatic dysfunction - Hematologic abnormalities such as thrombocytopenia

Levoleucovorin disodium requires careful clinical monitoring to minimise risk.

Renal function: assess baseline renal status and adjust dose in impairment. Hepatic function: monitor liver enzymes during therapy. Pregnancy: safety not established; use only if benefit outweighs potential risk. Concomitant methotrexate: avoid overlapping high‑dose methotrexate without appropriate rescue. Electrolyte balance: monitor serum electrolytes, especially potassium and magnesium. Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levoleucovorin disodium can interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - High‑dose methotrexate administered without rescue: may increase toxicity. - Other folate antagonists (e.g., trimethoprim, pyrimethamine): reduce therapeutic efficacy. - Nephrotoxic agents (e.g., cisplatin, aminoglycosides): heighten risk of renal injury.

Moderate Interactions (Monitor Closely): - NSAIDs: may affect renal clearance of levoleucovorin. - Proton pump inhibitors: potential alteration of folate metabolism. - Sulfonamides: competition for renal excretion pathways. - Antacids containing aluminum or magnesium: may affect concurrent oral folate absorption. - Warfarin: possible alteration of anticoagulant effect, requiring INR monitoring.